Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03162055 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,119
- Enrollment target
NCT03162055 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 1,119 participants.
The verdict
NCT03162055, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,119 participants
- Enrollment target
Study Summary
This is a phase IIIb randomised, double-blind, double-dummy, multicentre, parallel group, 24 week study to assess the efficacy and safety of Glycopyrronium/Formoterol Fumarate (GFF) fixed-dose combination 7.2/4.8 μg 2 inhalations twice daily compared to Umeclidinium/Vilanterol (UV) 62.5/25 μg fixed-dose combination 1 inhalation once daily in Patients with moderate to very severe COPD.
Interventions
- DRUG Glycopyrronium/Formoterol Fumarate
- DRUG umeclidinium/vilanterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,119 participants |
| Start Date | 2017-05-25 |
| Est. Completion | 2018-05-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03162055
The ClinicalTrials.gov registry entry for NCT03162055 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Glycopyrronium/Formoterol Fumarate is the first listed.
NCT03162055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03162055 about?
NCT03162055 is a clinical study titled "Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease". This is a phase IIIb randomised, double-blind, double-dummy, multicentre, parallel group, 24 week study to assess the efficacy and safety of Glycopyrronium/Formoterol Fumarate (GFF) fixed-dose combination 7.2/4.8 μg 2 inhalations twice daily compared to Umeclidinium/Vilanterol (UV) 62.5/25 μg fixed-...
What is the current status of trial NCT03162055?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,119 participants. The study started on 2017-05-25. Estimated completion is 2018-05-04.
What interventions are being tested in trial NCT03162055?
The interventions under investigation include: Glycopyrronium/Formoterol Fumarate (DRUG), umeclidinium/vilanterol (DRUG).
Who is sponsoring clinical trial NCT03162055?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.